NLS

When Sam Sihvonen, co-founder and CEO of Solu, sees a problem, he wants to fix it.

Nobel Prize laureate Mary E. Brunkow’s career path has shifted between industry and academia but her end goal to generate clinical benefit and her passion for exploring new areas have never wavered.

Imagine your job involves meeting with entrepreneurs and researchers who are passionate about developing drugs that could transform or save lives, and realizing you could be part of that future. That is just another “day at the office” for Ester Sklarsky, who has been a principal for the Swedish venture capital firm Sound Bioventures for the past three and a half years.

Despite international turbulence and news of life sciences and research funding disruptions in the U.S., investment in innovative life sciences projects continues, according to Mala Valroy, an investment manager with Industrifonden, one of Sweden’s largest evergreen venture capital (VC) funds. 


While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

“To be able to control costs and serve patients, the world will need biosimilars,” says Róbert Wessman, Icelandic businessman and entrepreneur.